Objectives: The aim of this study was to assess the efficacy of strontium ranelate in improving symptoms in knee OA.
Methods: Symptoms were assessed over 3 years in patients with primary knee OA receiving strontium ranelate 2 g/day (n = 454), 1 g/day (n = 445) or placebo (n = 472) in the Strontium Ranelate Efficacy in Knee Osteoarthritis Trial. Clinical response was evaluated using WOMAC subscores, minimal perceptible clinical improvement (MPCI), minimal clinically important improvement (MCII) and a modified OMERACT-Osteoarthritis Research Society International (OARSI) responder definition. Patients who withdrew prematurely from the study were considered non-responders.
Results: There was no significant effect on symptoms for strontium ranelate 1 g/day. At the dosage of 2 g/day, strontium ranelate was associated with greater response than placebo in terms of ≥20% improvement in WOMAC pain from baseline to the last visit (58% vs 47%, P = 0.002) and ≥50% improvement in WOMAC pain (42% vs 36%, P = 0.083). Significant differences were found in MPCI response for WOMAC pain (52% vs 40%, P < 0.001), stiffness (47% vs 39%, P = 0.009) and physical function (46% vs 37%, P = 0.009) and in MCII response for WOMAC physical function (46% vs 37%, P = 0.013). There were also more OMERACT-OARSI-like responders with strontium ranelate (44% vs 35%, P = 0.004). The treatment-placebo difference in MPCI response for WOMAC pain was significant after 6 months (P = 0.024), while that in MPCI and MCII response for WOMAC physical function reached significance after 12 months (P = 0.027 and P = 0.019, respectively).
Conclusion: Treatment with strontium ranelate 2 g/day over 3 years is associated with a clinically meaningful improvement in pain from 6 months as well as physical function and stiffness as assessed by the number of responders above thresholds of clinical relevance.
Trial Registration: Current Controlled Trials. http://www.controlled-trials.com/ (ISRCTN41323372).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/rheumatology/keu018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pregnancy- and Lactation-Associated Osteoporosis: A Literature Review Based on a Clinical Case.
Cureus
November 2024
Orthopedics and Traumatology, Santo António University Hospital Center, Porto, PRT.
Article Synopsis
- Pregnancy- and lactation-associated osteoporosis (PLO) is a rare condition impacting women postpartum, exemplified by a case of a 29-year-old with severe back pain due to vertebral fractures.
- Diagnosis involves ruling out other causes of osteoporosis, with treatment typically including calcium and vitamin D supplements alongside lactation suppression; however, pain may persist even after treatment.
- The condition remains poorly understood, with potential causes including genetic factors and calcium metabolism changes, highlighting the need for early diagnosis and personalized treatment strategies for better patient outcomes.
Repairing effect of magnesium oxychloride cement modified by γ-polyglutamic acid and chitosan in osteoporotic bone defect.
Int J Biol Macromol
December 2024
Henan Key Laboratory of Materials on Deep-Earth Engineering, School of Materials Science and Engineering, Henan Polytechnic University, Jiaozuo, China. Electronic address:
Magnesium oxychloride cement (MOC) has the advantage of high early strength. However, it has the defect of poor water resistance. Considering this performance, we use γ-polyglutamic acid (γ-PGA) and chitosan (CS) to modify MOC.
View Article and Find Full Text PDFMultiple vertebral fractures after antiosteoporotic medications discontinuation: A comparative study to evaluate the potential rebound effect of denosumab.
Bone
January 2025
Pharmacoepidemiology and Pharmacovigilance Department, Spanish Agency of Medicines and Medical Devices (AEMPS), Calle Campezo n° 1, Edificio 8, 28022 Madrid, Spain. Electronic address:
Article Synopsis
- Discontinuation of anti-osteoporotic medications, particularly Prolia® (denosumab), significantly increases the risk of multiple vertebral fractures (MVF) due to a rapid rise in bone turnover markers and loss of bone mineral density.
- A study using data from the Public Health System in Spain analyzed patients who had recently started various anti-osteoporotic medications, finding a strong association between denosumab discontinuation and a 2.82 times higher risk of MVF compared to those still on the medication.
- The risk of MVF after stopping denosumab was especially high within the first 3 to 9 months after discontinuation, increasing further after longer cumulative use of
Osteoarthritis year in review 2024: Imaging.
Osteoarthritis Cartilage
January 2025
Department of Radiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, USA; Department of Radiology, Boston VA Healthcare System, West Roxbury, MA, USA.
Objective: To review recent literature evidence describing imaging of osteoarthritis (OA) and to identify the current trends in research on OA imaging.
Method: This is a narrative review of publications in English, published between April, 2023, and March, 2024. A Pubmed search was conducted using the following search terms: osteoarthritis/OA, radiography, ultrasound/US, computed tomography/CT, magnetic resonance imaging/MRI, DXA/DEXA, and artificial intelligence/AI/deep learning.
Alleviating rheumatoid arthritis with a photo-pharmacotherapeutic glycan-integrated nanogel complex for advanced percutaneous delivery.
J Nanobiotechnology
October 2024
Graduate Institute of Biomedical Materials and Tissue Engineering, Graduate Institute of Nanomedicine and Medical Engineering, College of Biomedical Engineering, Taipei Medical University, New Taipei City, Taiwan.
The prospective of percutaneous drug delivery (PDD) mechanisms to address the limitations of oral and injectable treatment for rheumatoid arthritis (RA) is increasing. These limitations encompass inadequate compliance among patients and acute gastrointestinal side effects. However, the skin's intrinsic layer can frequently hinder the percutaneous dispersion of RA medications, thus mitigating the efficiency of drug delivery.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!